Fed. Circ. Bars Generic Of Horizon Arthritis Drug Until 2027
A split Federal Circuit on Thursday affirmed a lower court's decision that upheld the validity of a claim in one of the patents for Horizon's osteoarthritis drug Pennsaid 2%, a ruling...To view the full article, register now.
Already a subscriber? Click here to view full article